DNA Repair Genes in Cancer and Inherited Disease
DNA is damaged by replication errors, normal metabolism and environmental exposures. Dedicated pathways—including homologous recombination, mismatch repair, nucleotide-excision repair and base-excision repair—recognise different lesions and restore sequence or chromosome integrity. When repair is impaired through mutation or epigenetic silencing, characteristic genomic changes can accumulate. Some repair defects also function as treatment biomarkers, but evidence is specific to the altered gene or pathway, tumour type, assay, stage and regimen.
Quick Answer
Genes maintaining genome integrity through detection and correction of DNA damage. Their loss drives mutagenesis and cancer predisposition. This category links the major genes to their molecular mechanisms, cancer associations, and related pathway pages.
Key Genes in This Category
Pathways and evidence guides
Move from the gene list into a mechanism map or a focused interpretation guide.
DNA-damage response
Follow sensing, checkpoint signalling and cell-fate decisions.
Homologous recombination repair
Trace BRCA1, PALB2, BRCA2 and RAD51 function.
HRD testing, BRCA and ATM compared
Distinguish inherited variants, tumour findings and genomic-scar results.
BRCA1 and cancer risk
Separate inherited risk from tumour biomarker meaning.
Mismatch repair and Lynch syndrome
Connect MMR loss, MSI and inherited-risk context.
Core sources
Authoritative overviews and peer-reviewed sources supporting this category summary.
Explore Other Categories
Tumor Suppressor Genes
Proteins that act as molecular brakes on cell division. Loss of both copies unlocks uncontrolled proliferation.
Oncogenes
Gain-of-function mutations in growth-promoting genes that drive continuous cell division, even without normal growth signals.
Apoptosis Regulators
Genes that determine whether a damaged or stressed cell lives or dies. Cancer hijacks these to evade programmed cell death.
Cell Cycle Regulators
Proteins controlling when and how cells divide. Disruption of these checkpoints is nearly universal in human cancer.